Cirugia espanola · 2026
From trial to practice: real-world outcomes of neoadjuvant chemoimmunotherapy versus chemotherapy ± radiotherapy in resectable locally advanced NSCLC.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rivas Duarte Cristina E, Gómez-Hernández María Teresa, Manama Mario, Gómez Francisco, Taboada Carmen, Fuentes Marta G, Colmenares Oscar, Jiménez Marcelo F
Аннотация
BACKGROUND AND OBJECTIVES: Neoadjuvant chemotherapy combined with immune checkpoint inhibitors (ChT-ICI) has shown promising efficacy in resectable locally advanced non-small cell lung cancer (NSCLC), but real-world data comparing it with conventional chemotherapy or chemoradiotherapy (ChT/ChT-RT) are limited. This study evaluated perioperative safety and oncologic outcomes of both approaches in a real-world setting.
METHODS: A single-center retrospective analysis included consecutive patients with locally advanced NSCLC who received neoadjuvant therapy and underwent pulmonary resection between January 2017 and October 2025. Patients were grouped as ChT-ICI or ChT/ChT-RT. Primary endpoints were overall and cardiopulmonary morbidity; secondary endpoints included pathological complete response (pCR), overall survival (OS), and disease-free survival (DFS).
RESULTS: Eighty-two patients were analyzed (36 ChT-ICI, 46 ChT/ChT-RT). Overall complications occurred in 36.1% and 43.5%, and cardiopulmonary morbidity in 8.3% and 15.2%, respectively (adjusted OR 0.359; P = .211). pCR was significantly higher with ChT-ICI (33.3% vs 8.7%; adjusted OR 4.53; P = .021). No significant differences were observed in OS or DFS.
CONCLUSIONS: In this real-world cohort, neoadjuvant ChT-ICI demonstrated similar perioperative safety and a significantly higher pCR rate than conventional regimens, supporting its feasibility and therapeutic potential in resectable locally advanced NSCLC.
METHODS: A single-center retrospective analysis included consecutive patients with locally advanced NSCLC who received neoadjuvant therapy and underwent pulmonary resection between January 2017 and October 2025. Patients were grouped as ChT-ICI or ChT/ChT-RT. Primary endpoints were overall and cardiopulmonary morbidity; secondary endpoints included pathological complete response (pCR), overall survival (OS), and disease-free survival (DFS).
RESULTS: Eighty-two patients were analyzed (36 ChT-ICI, 46 ChT/ChT-RT). Overall complications occurred in 36.1% and 43.5%, and cardiopulmonary morbidity in 8.3% and 15.2%, respectively (adjusted OR 0.359; P = .211). pCR was significantly higher with ChT-ICI (33.3% vs 8.7%; adjusted OR 4.53; P = .021). No significant differences were observed in OS or DFS.
CONCLUSIONS: In this real-world cohort, neoadjuvant ChT-ICI demonstrated similar perioperative safety and a significantly higher pCR rate than conventional regimens, supporting its feasibility and therapeutic potential in resectable locally advanced NSCLC.